Global Veterinary Dermatology Drugs Market Size (2024 - 2029)

Veterinary Dermatology Drugs Market Analysis

The Global Veterinary Dermatology Drugs Market size is estimated at USD 6.38 billion in 2024, and is expected to reach USD 9.01 billion by 2029, growing at a CAGR of 7.11% during the forecast period (2024-2029).

Factors such as an increasing burden of dermatological diseases in pet animals and increasing pet adoption and animal care are expected to garner the demand for the availability of dermatology drugs available for veterinary use. They are anticipated to drive the overall market growth during the forecast period.

Most animals globally are affected by major skin diseases like parasitic skin diseases, alopecia, dander-related skin disorders, intrinsic skin infections, mild to harmful skin cancer, autoimmune skin diseases, and other internal skin abnormalities. For instance, according to a study published in the Veterinary Sciences Journal in July 2022, atopic dermatitis (AD) is one of the most common pet allergies. In dogs, the prevalence has become increasingly common due to rising exposure to indoor environments and processed foods for pets. Hence, the burden of AD among canines is rising and is creating demand for the availability of dermatology drugs. This is anticipated to fuel the growth of the market in the country.

Moreover, increasing pet adoption is expected to contribute to the growth of the market over the forecast period. For instance, According to the 2023-2024 American Pet Product Association (APPA) National Pet Owners Survey, about 66% of households in the United States owned a pet, which translates to about 86.9 million homes. Cats and dogs were the major pets, with a total population of 45.3 million and 69 million, respectively.

Furthermore, the growing availability of research sources and company research and development activities to innovate new products are the factors fueling competitiveness in the market. For instance, in September 2022, Boehringer Ingelheim announced today the U.S. Food and Drug Administration has approved SPEVIGO, the first approved treatment option for generalized pustular psoriasis (GPP) flares in adults. SPEVIGO is a novel, selective antibody that blocks the activation of the interleukin-36 receptor (IL-36R), a key part of a signaling pathway within the immune system shown to be involved in the cause of GPP. As better dermatological health is crucial for pets, pet owners, and livestock animals, the increasing number of products is expected to contribute to the growth of the veterinary dermatology drugs market.

However, the low availability and lack of awareness of the drugs might restrain the market growth over the analysis period.

Veterinary Dermatology Drugs Industry Segmentation

As per the scope of this report, veterinary dermatology is also known as veterinary skin care. Skin disorders are the most common medical conditions that are seen in animals due to licking, biting, repeatedly shaking their heads, and excessive scratching of their fur and skin. Veterinary dermatology drugs are used to treat skin infections or skin diseases in animals, mostly companion animals and livestock animals. The veterinary dermatology drugs market is segmented by animal, route of administration, distribution channel, and geography. By animal, the market is segmented as companion animal, livestock animal. By route of administration, the market is segmented as topical, injectable, and oral. By indication, the market is segmented as parasitic infections, allergic infections, and other indications. By distribution channel, the market is segmented as retail, hospital pharmacies, and e-commerce). By geography, the market is segmented as North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD) for the above segments.